GRDN Stock Analysis: Guardian Pharmacy Services | NYSE
Medical Care Facilities | NYSE, USA | Market Cap: 2.347m USD | 12M Return: 46.1% | US40145W1018 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 12.9M
Qual. Beats: 0
Rev. Trend: 99.2%
Qual. Beats: 2
Warnings
Tailwinds
Seasonality 1.8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Guardian Pharmacy Services (NYSE: GRDN) is a US pharmacy services company that provides technology-enabled clinical, dispensing, and administrative support to residents of long-term care facilities (LTCFs), with a focus on lower-acuity settings such as assisted living communities, behavioral health facilities, and group homes. Its proprietary platform, branded Guardian Compass, offers data-driven tools-including dashboards, the GuardianShield programs, an Order Entry QA Analyzer for prescription error detection, and a Medication Spend Analyzer-to help its local pharmacy partners and facility clients manage operations and drug costs. Headquartered in Atlanta, Georgia, and founded in 2003, the company operates within the GICS Consumer Staples / Drug Retail segment and completed its IPO in late September 2024. As a specialty LTC pharmacy operator, Guardian benefits from the fragmented nature of institutional pharmacy services and rising demand tied to the aging US population and the growing preference for non-institutional long-term care settings.
- Acquisition strategy expands pharmacy footprint across assisted living markets
- Aging US population drives long-term care facility resident growth
- Drug reimbursement rate changes pressure pharmacy gross margins
| Net Income: 65.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.18 > 0.02 and ΔFCF/TA 7.34 > 1.0 |
| NWC/Revenue: 6.88% < 20% (prev 2.00%; Δ 4.88% < -1%) |
| CFO/TA 0.22 > 3% & CFO 98.9m > Net Income 65.9m |
| Net Debt (-54.6m) to EBITDA (115.1m): -0.47 < 3 |
| Current Ratio: 1.65 > 1.5 & < 3 |
| Outstanding Shares: last quarter (63.8m) vs 12m ago 1.00% < -2% |
| Gross Margin: 21.63% > 18% (prev 19.63%; Δ 2.00% > 0.5%) |
| Asset Turnover: 365.9% > 50% (prev 372.3%; Δ -6.40% > 0%) |
| Interest Coverage Ratio: 145.4 > 6 (EBIT TTM 91.7m / Interest Expense TTM 631k) |
| A: 0.23 (Total Current Assets 254.7m - Total Current Liabilities 154.0m) / Total Assets 443.6m |
| B: 0.23 (Retained Earnings 101.5m / Total Assets 443.6m) |
| C: 0.23 (EBIT TTM 91.7m / Avg Total Assets 400.0m) |
| D: 1.32 (Book Value of Equity 245.6m / Total Liabilities 185.9m) |
| Altman-Z'' = 5.16 = AAA |
| DSRI: 1.00 (Receivables 103.8m/94.1m, Revenue 1.46b/1.33b) |
| GMI: 0.91 (GM 19.63% / 21.63%) |
| AQI: 0.81 (AQ_t 0.23 / AQ_t-1 0.28) |
| SGI: 1.10 (Revenue 1.46b / 1.33b) |
| TATA: -0.07 (NI 65.9m - CFO 98.9m) / TA 443.6m) |
| Beneish M = -3.16 (Cap -4..+1) = AA |
As of September 02, 2026, the stock is trading at USD 38.87 with a total of 537,258 shares traded. Over the past week, the price has changed by +4.21%, over one month by -4.75%, over three months by -0.99% and over the past year by +46.13%.
Current recommended Stop Loss: 36.90 (which is 5.1% or 1.3 ATR below the current price).
Guardian Pharmacy Services has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy GRDN.
- StrongBuy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 48.8 | 25.6% |
P/E Trailing = 35.6346
P/E Forward = 28.9017
P/S = 1.6041
P/B = 9.6272
Revenue TTM = 1.46b USD
EBIT TTM = 91.7m USD
EBITDA TTM = 115.1m USD
Long Term Debt = 27.9m USD (estimated: total debt 35.2m - short term 7.38m)
Short Term Debt = 7.38m USD (from shortTermDebt, last quarter)
Debt = 35.2m USD (from shortLongTermDebtTotal, last quarter) (leases 35.2m already included)
Net Debt = -54.6m USD (calculated: Debt 35.2m - CCE 89.8m)
Enterprise Value = 2.29b USD (2.35b + Debt 35.2m - CCE 89.8m)
Interest Coverage Ratio = 145.4 (Ebit TTM 91.7m / Interest Expense TTM 631k)
EV/FCF = 28.74x (Enterprise Value 2.29b / FCF TTM 79.8m)
FCF Yield = 3.48% (FCF TTM 79.8m / Enterprise Value 2.29b)
FCF Margin = 5.45% (FCF TTM 79.8m / Revenue TTM 1.46b)
Net Margin = 4.50% (Net Income TTM 65.9m / Revenue TTM 1.46b)
Gross Margin = 21.63% ((Revenue TTM 1.46b - Cost of Revenue TTM 1.15b) / Revenue TTM)
Gross Margin QoQ = 22.75% (prev 22.67%)
Tobins Q-Ratio = 5.17 (Enterprise Value 2.29b / Total Assets 443.6m)
Interest Expense / Debt = 1.79% (Interest Expense 631k / Debt 35.2m)
Taxrate = 30.57% (29.3m / 95.8m)
NOPAT = 63.7m (EBIT 91.7m * (1 - 30.57%))
Current Ratio = 1.65 (Total Current Assets 254.7m / Total Current Liabilities 154.0m)
Debt / Equity = 0.14 (Debt 35.2m / totalStockholderEquity, last quarter 245.6m)
Debt / EBITDA = -0.47 (Net Debt -54.6m / EBITDA 115.1m)
Debt / FCF = -0.68 (Net Debt -54.6m / FCF TTM 79.8m)
Total Stockholder Equity = 214.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 16.48% (Net Income 65.9m / Total Assets 443.6m)
RoE = 30.80% (Net Income TTM 65.9m / Total Stockholder Equity 214.0m)
RoCE = 37.93% (EBIT 91.7m / Capital Employed (Equity 214.0m + L.T.Debt 27.9m))
RoIC = 28.47% (NOPAT 63.7m / Invested Capital 223.7m)
WACC = 7.20% (E(2.35b)/V(2.38b) * Re(7.29%) + D(35.2m)/V(2.38b) * Rd(1.79%) * (1-Tc(0.31)))
Discount Rate = 7.29% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 93.91 | Cagr: 2.16%
[DCF] Terminal Value 77.97% ; FCFF base≈63.0m ; Y1≈72.3m ; Y5≈106.4m
[DCF] Fair Price = 33.23 (EV 1.60b - Net Debt -54.6m = Equity 1.66b / Shares 49.8m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: 99.15 | Revenue CAGR: 16.21% | SUE: 1.63 | # QB: 2
EPS current Quarter (2026-09-30): EPS=0.32 | Chg30d=+4.41% | Revisions=+57% | Analysts=6
EPS current Year (2026-12-31): EPS=1.30 | Chg30d=+3.44% | Revisions=+57% | GrowthEPS=+21.8% | GrowthRev=-0.5%
EPS next Year (2027-12-31): EPS=1.43 | Chg30d=+5.28% | Revisions=+62% | GrowthEPS=+9.7% | GrowthRev=+6.5%
[Analyst] Revisions Ratio: +81% (up=13, down=0)